BriaCell Therapeutics Corp.’s (OTCQB: BCTXF) (TSX.V: BCT) Development of Personalized Immunotherapy Focuses on Advanced Breast Cancer
- Experienced management has been involved in over 10 drug approvals
- Developing Bria-OTS, the first off-the-shelf personalized immunotherapy targeting advanced breast cancer
- Impressive results in two proof-of-concept clinical trials revealed rapid response rate, repeated following re-treatment, and excellent safety profile for Bria-IMT, BriaCell’s lead clinical candidate
- Unmet medical needs of advanced breast cancer estimated between $1 billion and $5 billion, depending on treatment stage
- Developing Bria-OTS along with BriaDX, a companion diagnostic test, offering the ability to match and treat over 99 percent of the patient population with off-the-shelf personalized immunotherapy
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company, is tackling problems in the cancer immunotherapy space with solutions that focus on off-the-shelf personalized immunotherapy treatments that are expected to be highly effective and safe. BriaCell has been developing Bria-OTS, an off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer. The World Cancer Research Fund of the American Institute for Cancer Research states that breast cancer is the most commonly occurring cancer in women and the second most common cancer overall, with over two million new cases reported in 2018 (http://nnw.fm/S2rNC).
Initial data from a combination study of Bria-IMT and KEYTRUDA (pembrolizumab/Merck) has demonstrated an excellent safety profile, as the company announced at the 2018 San Antonio Breast Cancer Symposium (http://nnw.fm/Po3A0). Confirmation of Bria-IMT’s mechanism of action and positive proof-of-concept data for use as a monotherapy for the treatment of advanced breast cancer – demonstrated in an FDA-approved clinical trial – was also shared at the conference.
“I am very excited about our data continuing to show robust biological activity of Bria-IMT in advanced breast cancer,” Bill Williams, BriaCell’s president and CEO, stated in a news release (http://nnw.fm/8S0qW). “These findings also reinforce our product development strategy for Bria-OTS, BriaCell’s novel off-the-shelf personalized immunotherapy, by showing predictability of the anti-tumor responses in patients using a relatively simple and inexpensive HLA test.”
“Based on the data of three proof of concept studies to-date, Bria-IMT has shown the ability to produce powerful immune responses and elicit tumor regression even in heavily pre-treated patients with very advanced disease,” Williams continued.
“We are highly confident of our strategy to use Bria-IMT in combination with KEYTRUDA, an approved treatment for multiple cancer indications and expect synergistic activity of this combination in patients with advanced breast cancer,” Williams added. “We look forward to additional clinical data and expect to share details at the Keystone meeting and other upcoming scientific meetings.”
Fighting cancer is costly, as patients and their caregivers know all too well. Cancer has a major impact on multiple levels, costing more than $180 billion per year in health care expenses and lost productivity, according to the American Cancer Society (http://nnw.fm/9WmFX).
BriaCell’s development of Bria-OTS, a personalized immunotherapy solution that matches the needs of the patient without a specialized manufacturing process, is designed to mitigate some of those worries. This personalized treatment is expected to be safe and highly effective while avoiding the high costs of creating personalized treatments for advanced cancer patients. In addition, Bria-OTS is created to produce a selective immune response that’s tailored to the specific needs of the cancer patient. Bria-OTS is expected to cover over 99 percent of the patient population, according to the company’s research data (http://nnw.fm/7tRQ9).
For more information, visit the company’s website at www.BriaCell.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Experienced management has been involved in over 10 drug approvals
- Developing Bria-OTS, the first off-the-shelf personalized immunotherapy targeting advanced breast cancer
- Impressive results in two proof-of-concept clinical trials revealed rapid response rate, repeated following re-treatment, and excellent safety profile for Bria-IMT, BriaCell’s lead clinical candidate
- Unmet medical needs of advanced breast cancer estimated between $1 billion and $5 billion, depending on treatment stage
- Developing Bria-OTS along with BriaDX, a companion diagnostic test, offering the ability to match and treat over 99 percent of the patient population with off-the-shelf personalized immunotherapy
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company, is tackling problems in the cancer immunotherapy space with solutions that focus on off-the-shelf personalized immunotherapy treatments that are expected to be highly effective and safe. BriaCell has been developing Bria-OTS, an off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer. The World Cancer Research Fund of the American Institute for Cancer Research states that breast cancer is the most commonly occurring cancer in women and the second most common cancer overall, with over two million new cases reported in 2018 (http://nnw.fm/S2rNC).
Initial data from a combination study of Bria-IMT and KEYTRUDA (pembrolizumab/Merck) has demonstrated an excellent safety profile, as the company announced at the 2018 San Antonio Breast Cancer Symposium (http://nnw.fm/Po3A0). Confirmation of Bria-IMT’s mechanism of action and positive proof-of-concept data for use as a monotherapy for the treatment of advanced breast cancer – demonstrated in an FDA-approved clinical trial – was also shared at the conference.
“I am very excited about our data continuing to show robust biological activity of Bria-IMT in advanced breast cancer,” Bill Williams, BriaCell’s president and CEO, stated in a news release (http://nnw.fm/8S0qW). “These findings also reinforce our product development strategy for Bria-OTS, BriaCell’s novel off-the-shelf personalized immunotherapy, by showing predictability of the anti-tumor responses in patients using a relatively simple and inexpensive HLA test.”
“Based on the data of three proof of concept studies to-date, Bria-IMT has shown the ability to produce powerful immune responses and elicit tumor regression even in heavily pre-treated patients with very advanced disease,” Williams continued.
“We are highly confident of our strategy to use Bria-IMT in combination with KEYTRUDA, an approved treatment for multiple cancer indications and expect synergistic activity of this combination in patients with advanced breast cancer,” Williams added. “We look forward to additional clinical data and expect to share details at the Keystone meeting and other upcoming scientific meetings.”
Fighting cancer is costly, as patients and their caregivers know all too well. Cancer has a major impact on multiple levels, costing more than $180 billion per year in health care expenses and lost productivity, according to the American Cancer Society (http://nnw.fm/9WmFX).
BriaCell’s development of Bria-OTS, a personalized immunotherapy solution that matches the needs of the patient without a specialized manufacturing process, is designed to mitigate some of those worries. This personalized treatment is expected to be safe and highly effective while avoiding the high costs of creating personalized treatments for advanced cancer patients. In addition, Bria-OTS is created to produce a selective immune response that’s tailored to the specific needs of the cancer patient. Bria-OTS is expected to cover over 99 percent of the patient population, according to the company’s research data (http://nnw.fm/7tRQ9).
For more information, visit the company’s website at www.BriaCell.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
